Orexo AB
ORX SE0000736415
ICB 2010 : Health Care / Health CareSweden 751 05
SE-C UPPSALA Box 303
Registration Number 556500-0600
Orexo is a Swedish pharmaceutical company that develops improved pharmaceuticals based on innovative formulation technologies that meet large medical needs. Through presence its in the US market, drugs and digital therapies are commercialized to treat opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with partners.
Founded 1994
Employees 126
http://www.orexo.com/
https://en.wikipedia.org/wiki/Orexo
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -52% | -50% | -22% | 18% | 5% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Transactions: 65 Insiders: 17
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Nikolaj Arrild Sørensen |
14.30 SEK |
2,460 Bought |
35,178 SEK |
17/04/2025 | 11/04/2025 |
| Nikolaj Arrild Sørensen |
13.58 SEK |
3,500 Bought |
47,530 SEK |
08/04/2025 | 04/04/2025 |
| Christine Elizabeth Rankin DIR |
21.28 SEK |
2,332 Bought |
49,625 SEK |
10/06/2024 | 07/06/2024 |
| Staffan Lindstrand DIR |
21.24 SEK |
3,301 Bought |
70,119 SEK |
05/06/2024 | 05/06/2024 |
| James Noble CB |
20.80 SEK |
13,066 Bought |
271,773 SEK |
07/06/2024 | 05/06/2024 |
| Fredrik Järrsten CFO |
14.68 SEK |
3,000 Bought |
44,040 SEK |
26/03/2024 | 26/03/2024 |
| Nikolaj Arrild Sørensen CEO |
15.48 SEK |
2,069 Bought |
32,028 SEK |
28/02/2024 | 28/02/2024 |
| Nikolaj Arrild Sørensen CEO |
15.00 SEK |
2,941 Bought |
44,115 SEK |
28/02/2024 | 27/02/2024 |
| Nikolaj Arrild Sørensen CEO |
14.35 SEK |
5,000 Bought |
71,750 SEK |
28/02/2024 | 26/02/2024 |
| Charlotte Vithlani Hansson DIR |
14.88 SEK |
3,000 Bought |
44,640 SEK |
25/11/2023 | 24/11/2023 |